Unyielding dedication to safety

HUMATE-P is a made in a multi-step process that provides purity and safety every step of the way. Plasma collection, processing, and packaging procedures are designed to retain the properties of the VWF and FVIII proteins.

CSL Behring’s Integrated Safety System includes 3 steps specifically designed to identify and remove live viruses. However, the risk of viral transmission cannot be completely eliminated.


3 steps to inactivate and remove viral pathogens

Virus inactivation
Virus Reduction
Virus removal

HUMATE-P has a proven safety record established in 30+ years of clinical use

5.2 billion IU distributed since 1990

5.2 billion IU

distributed since 1990

NO documented viral transmission


documented viral transmission

Most common adverse reactions to HUMATE-P

In studies, more than 5% of patients reported the following adverse reactions to HUMATE-P: allergic/anaphylactic reactions, including hives, chest tightness, rash, itching, and swelling. The most common adverse reactions after surgery were bleeding at the wound or infusion site, and nosebleeds.

In 63 people who received HUMATE-P for surgery-related bleeding, the most common adverse events were postoperative bleeding (19 people, with 5 people experiencing bleeding at up to three different sites), postoperative nausea (15 people), and postoperative pain (11 people).

In 97 people who received HUMATE-P for on-demand use,

4 people experienced 7 adverse events that were considered to have a possible or probable relationship to HUMATE-P. These included chills, blood vessel inflammation, blood vessel widening, abnormal sensation on the skin, itching, rash, and hives. All were mild in intensity with the exception of a moderate case of itching.

Icon of shield

30+ years of safe,

effective bleed control

Icon of dollar sign

The support you need

when you need it

You are now leaving the current website.

Do you want to continue?

Yes No